SCHEMBL5145120

SCHEMBL5145120

CN1C(=O)NC(=O)C(=Cc2ccc(-c3ccc([N+](=O)[O-])cc3)o2)C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.68
MAPT P10636 8/20 0.67
MEN1 O00255 8/20 0.67
KMT2A Q03164 8/20 0.67
TDP1 Q9NUW8 5/20 0.67
KDM4E B2RXH2 4/20 0.67
ALDH1A1 P00352 3/20 0.67
POLB P06746 3/20 0.67
L3MBTL1 Q9Y468 3/20 0.67
NSD2 O96028 1/20 0.67
DNMT1 P26358 1/20 0.67
GSK3A P49840 1/20 0.57
GSK3B P49841 1/20 0.57
DUSP3 P51452 1/20 0.53
RET P07949 2/20 0.52
RECQL P46063 3/20 0.51
BLM P54132 2/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5145115 1.00 BRAF (0.68) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL6397256 0.87 BRAF (0.70) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL6396866 0.87 BRAF (0.70) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL5163163 0.84 MEN1 (0.61) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL5163154 0.84 MEN1 (0.61) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL5163906 0.83 BRAF (0.81) BRAFMAPTMEN1KMT2AKDM4E
SCHEMBL3760817 0.83 PIK3CG (0.61) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL3760819 0.83 PIK3CG (0.61) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL3760822 0.83 PIK3CG (0.61) BRAFMAPTMEN1KMT2ATDP1
SCHEMBL22830596 0.81 KMT2A (1.00) MAPTMEN1KMT2ATDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed
US-6869950-B1 Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-03-22 US disclosed
EP-1142880-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 BRAF 4079/4885MAPT 2096/4885MEN1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.